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Purpose: Mutations in bestrophin 1 (BEST1) are associated with a group of retinal disorders known as bestrophinopathies
in man and canine multifocal retinopathies (cmr) in the dog. To date, the dog is the only large animal model suitable for
the complex characterization and in-depth studies of Best-related disorders. In the first report of cmr, the disease was
described in a group of mastiff-related breeds (cmr1) and the Coton de Tulear (cmr2). Additional breeds, e.g., the
Lapponian herder (LH) and others, subsequently were recognized with similar phenotypes, but linked loci are unknown.
Analysis of the BEST1 gene aimed to identify mutations in these additional populations and extend our understanding of
genotype–phenotype associations.
Methods: Animals were subjected to routine eye exams, phenotypically characterized, and samples were collected for
molecular studies. Known BEST1 mutations were assessed, and the canine BEST1 coding exons were amplified and
sequenced in selected individuals that exhibited a cmr compatible phenotype but that did not carry known mutations.
Resulting sequence changes were genotyped in several different breeds and evaluated in the context of the phenotype.
Results: Seven novel coding variants were identified in exon 10 of cBEST1. Two linked mutations were associated with
cmr exclusive to the LH breed (cmr3). Two individuals of Jämthund and Norfolk terrier breeds were heterozygous for
two conservative changes, but these were unlikely to have disease-causing potential. Another three substitutions were
found in the Bernese mountain dog that were predicted to have a deleterious effect on protein function. Previously reported
mutations were excluded from segregation in these populations, but cmr1 was confirmed in another mastiff-related breed,
the Italian cane corso.
Conclusions: A third independent canine model for human bestrophinopathies has been established in the LH breed.
While exhibiting a phenotype comparable to cmr1 and cmr2, the novel cmr3 mutation is predicted to be based on a distinctly
different molecular mechanism. So far cmr2 and cmr3 are exclusive to a single dog breed each. In contrast, cmr1 is found
in multiple related breeds. Additional sequence alterations identified in exon 10 of cBEST1 in other breeds exhibit potential
disease-causing features. The inherent genetic and phenotypic variation observed with retinal disorders in canines is
complicated further by cmr3 being one of four distinct genetic retinal traits found to segregate in LH. Thus, a combination
of phenotypic, molecular, and population analysis is required to establish a strong phenotype–genotype association. These
results indicate that cmr has a larger impact on the general dog population than was initially suspected. The complexity
of these models further confirms the similarity to human bestrophinopathies. Moreover, analyses of multiple canine models
will provide additional insight into the molecular basis underlying diseases caused by mutations in BEST1.
A major challenge in the description, interpretation, and
therapy for genetically caused diseases is identifying unique
phenotypic  disease  characteristics  and  discerning  their
underlying genotype. On one hand, genetic heterogeneity can
result in the same phenotype in a single population, which is
caused by mutations in one (allelic heterogeneity) or more
(nonallelic heterogeneity) loci. On the other hand, individual
loci or genes can be associated with several distinctly different
disorders,  commonly  known  as  a  pleiotropic  effect.  Both
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phenomena are common to blinding disorders. For example,
a single retinal phenotype, such as retinitis pigmentosa, is
linked  to  several  genes  and  loci  (>40  loci,  RetNet).
Conversely,  alterations  in  frequently  mutated  genes  in
humans,  e.g.,  retinal-specific  ATP-binding  cassette
transporter  (ABCA4)  or  bestrophin  1  (BEST1),  result  in
pleiotropic effects and are associated with large numbers of
overlapping  phenotypes  [1-4].  Diagnoses  are  further
complicated as, in many cases, the disease-causing mutation
and modifying alleles are not yet known. Mutations in the
BEST1 (also known as VMD2) gene cause several human
retinal disorders grouped as bestrophinopathies [5-7]. Despite
differences in the clinical appearance and mode of inheritance
between individual patients, these disorders predominantly
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2791affect the macula and fovea area, with varying involvement
of the peripheral retina having been reported [8-10].
Autosomal dominant Best vitelliform macular dystrophy
(BVMD), the most prominent bestrophinopathy phenotype,
typically  presents  in  childhood  with  the  appearance  of  a
single, yolk-like lesion of the macula. However, variation
occurs  in  the  disease  manifestation,  which  can  extend  to
multifocal vitelliform, atrophic lesions, or chorioretinal scars.
Additionally,  the  age  of  onset  and  progression  within
individual  pedigrees  is  not  consistent.  As  a  consequence,
visual impairment in patients ranges from minor dropout of
central vision to complete central blindness following atrophy
of  the  retinal  pigment  epithelium  and  photoreceptor
degeneration  [10-12].  Overlapping  clinical  presentation
between BVMD and other bestrophinopathies [4], caused by
well over 100 different mutations in BEST1, demonstrates the
complexity  of  genotype–phenotype  associations.  These
intricacies  hamper  development  of  allele-  and  phenotype-
independent therapy options. The lack of a clear prognosis and
of treatment options adds to the emotional strain for children
and young adults with early onset bestrophinopathies.
The development of large animal models complements
ongoing  research  in  rodents,  the  latter  of  which  do  not
necessarily  recapitulate  the  complexity  of  the  human
phenotype [13]. The particular population structure of the dog
is  a  direct  result  of  separating  isolated  breeds  for  many
generations and proves advantageous for tracking phenotypic
and disease traits [14,15]. Identification of mutations causing
canine blinding disorders has not only improved breeding
strategies  but  has  also  significantly  advanced  the
understanding of disease mechanisms and development of
therapies [16]. To this end, several experimental studies in
dogs have formed the basis for human clinical trials, and many
more are expected to follow suit [17-19]. As the molecular
bases of inherited retinal disorders are being discovered, it
appears  that  simple  mutation–breed  associations  are  not
necessarily the rule. While these do occur [20,21], one cannot
predict the number of breeds associated with either allelic
[22] or nonallelic [23,24] forms of disease.
Two  mutations  in  canine  BEST1  (cBEST1)  have
previously  been  described  in  different  dog  breeds  and
established the canine bestrophinopathy models [24]. Both the
C73T premature stop mutation (R25X) in Great Pyrenees and
mastiff-related  breeds,  and  the  G482A  missense  mutation
(G161D) in the Coton de Tulear present with a characteristic
clinical manifestation termed canine multifocal retinopathy
(cmr). The autosomal recessive, post-developmental disease
phenotype results in early onset of retinal elevations, with
areas containing subretinal pink-tan fluid that develop into
focal to multifocal outer retinal atrophy. Similar lesions have
been recognized in other canine populations, but thus far the
responsible genetic defects are unknown. One of these breeds,
the Lapponian herder (LH), native to Finland, is known to also
be  affected  by  progressive  rod–cone  degeneration  (prcd)
[22,25],  the  most  common  retinal  degeneration  in  dogs
distributed in >20 distinct breeds. However, after eliminating
prcd-affected animals, phenotypic variation in LH with retinal
abnormalities remained, with pathologies including lesions
mimicking cmr, multifocal retinal dysplasia (MRD), post-
inflammatory changes, and generalized progressive retinal
atrophy  (PRA).  Based  on  the  onset  of  the  multifocal
retinopathy at approximately 1 year of age, and similarities in
the disease manifestation to cmr, we hypothesized that at least
a subset of the spectrum of retinal diseases in LH could be
explained by mutations in cBEST1.
To examine the association of known and new cBEST1
mutations in LH and other breeds, a total of 614 dogs from 38
different breeds were assessed for cmr1 and cmr2 mutations
(Table 1). The presence of the cmr1 mutation was confirmed
in additional mastiff-related dog populations, including the
Italian cane corso (also known as Italian mastiff), but was not
present in a large LH pedigree or isolated cases of other
breeds. Notably, seven novel coding changes in cBEST1 exon
10 were recognized in those samples. Two of these were
associated with one (cmr3) of four different retinal diseases
in  the  LH.  The  presented  variation  among  and  within
individual  cmr  genotypes  appears  comparable  to  human
BVMD [5]. Thus, the different molecular consequences and
independent  breed  backgrounds  of  the  canine
bestrophinopathy  models  will  provide  a  solid  basis  for
investigating genotype–phenotype correlations with regard to
BEST1 mutations and, most importantly, present insights for
potential therapeutic intervention.
METHODS
Sample collection: Blood in anticoagulant or buccal swabs
were obtained from privately owned dogs in accordance with
standard clinical veterinary care and forwarded to research
laboratories as part of ongoing research at the University of
Pennsylvania,  the  University  of  Helsinki  and  Folkhälsan
Research  Center,  or  the  University  of  Zurich.  DNA  was
extracted using the DNeasy Blood & Tissue Kit (Qiagen Inc.,
Valencia,  CA)  following  the  manufacturer’s  protocol  and
stored at −80 °C until further use. After exclusion of other
known retinal disorders in the respective breeds (prcd [22];
X-linked PRA [23]; Collie Eye Anomaly [26]), 614 samples
from 38 individual breeds were enrolled in the current study
as normal controls and dogs with retinal disease of unknown
cause (Table 1).
Phenotype evaluation: Except for most Bernese mountain
dogs  (BMD)  and  mastiffs,  all  dogs  received  routine
ophthalmic  examination  following  the  guidelines  of  the
Canine Eye Registration Foundation, American College of
Veterinary Ophthalmologists, and the European College of
Veterinary Ophthalmology hereditary eye disease scheme.
All LH in the study were phenotypically evaluated by one of
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2792TABLE 1. DOG BREEDS SCREENED FOR CBEST1.
Evaluated Breed # mutation/disease
cBEST1 coding region Karelian bear dog 2  
  Kuvasz 1  
  Lapponian herder 5 P463fs
      G489V
  Swedish vallhund 2  
cBEST1 exon 10 Affenpinscher 1  
  Akita 1  
  Basenji 4  
  Belgian shepherd dog 1  
  Bernese mountain dog 135 K438R
      W440C
      V473G
  Border collie 1  
  Cavalier King Charles Spaniel 1  
  Great dane 1  
  Havanese 1  
  Ibizan hound 1  
  Jämthund 1 T505S
  Karelian bear dog 4  
  Miniature spitz 2  
  Lancashire heeler 1  
  Löwchen 1  
  Miniature schnauzer 2  
  Norfolk terrier 1 W440L
  Norrbottenspetz 1  
  Parson russel terrier 5  
  Rottweiler 1  
  Russian hound 1  
  Tibetan spaniel 2  
cmr mutations Affenpinscher 1  
  Akita 1  
  Argentinean mastiff 19  
  Basenji 4  
  Belgian shepherd dog 1  
  Bernese mountain dog 392  
  Border collie 1  
  Cavalier King Charles Spaniel 1  
  Dogue de Bordeaux 30 cmr1
  English mastiff 2 cmr1
  Finnish lapphund 1  
  German shorthaired pointer 4  
  Great dane 1  
  Havanese 1  
  Ibizan hound 1  
  Irish setter 5  
  Italian cane corso 44 cmr1
  Jämthund 1  
  Karelian bear dog 6  
  Miniature spitz 2  
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2793the co-authors (KW); this represented a total of 70 animals
based on data covering more than 10 years. However, DNA
was available from only 54 of these dogs. Dogs included in
the genetic study were examined between 1 and 2 years of age
in most cases; follow-up exams were scheduled every 1–2
years depending on findings. Although cmr lesions develop
before 2 years of age, only dogs with no changes after 3 years
of age were considered nonaffected. These stringent criteria
identified a total of eight cmr-affected LH and 46 that were
either normal or had other fundus changes.
BEST1 sequence comparison: All coding exons and flanking
splice  junctions  of  cBEST1  (exons  2  through  11)  were
amplified individually from dogs with clinical disease similar
to cmr and three obligate carrier LH dogs (Table 1), using
gene-specific primers and conditions previously published
[24]. Amplification products were visualized on 1% agarose
gels  and  purified  using  the  QIAquick  Gel  Extraction  Kit
(Qiagen Inc., Valencia, CA). Sequences were obtained by
direct sequencing of the direct and indirect strand (ABI 3730
sequencer; Applied Biosystems, Foster City, CA) at the DNA
Sequencing Facility of the University of Pennsylvania and
evaluated with the Sequencher 4.2.2 software package (Gene
Codes Corporation, Ann Arbor, MI).
Additional  breeds  harboring  molecularly  undefined
retinal changes were selected based on a potentially shared
ancestral or geographic origin with LH (Table 1). From these,
cBEST1 Exon 10 was amplified under the same conditions;
forward primer 5′- AAG GAG GGA AAA GAT AGG GT
−3′, reverse primer 5′- AGG TGG AAG GAG GGT AGA AT
−3′), and sequenced in both directions (forward primer 5′-
CTC ACC CAG GTG TGT GTT TG −3′, reverse primer 5′-
TCA  AGT  CCT  GCT  TTG  GTC  CT  −3′).  All  obtained
sequences were aligned against the canine genome sequence
draft  [27]  and  cBEST1  reference  sequence
(NM_001097545).  Observed  sequence  alterations  were
analyzed for their potential to affect protein function using the
Sorting Intolerant From Tolerant (SIFT) algorithm [28,29].
Mutation screening and testing:
Allele-specific  PCR  amplification—Confirmed  cmr
mutations were tested in all enrolled dogs (Table 1). Tests for
cmr1  (C73T/R25X)  and  cmr2  (G482A/G161D)  mutations
followed published protocols [24]; for the cmr3 sequence
variations, tests were established for amplification of the wild
type  (WT)  or  mutation  (LH)-specific  allele.  Two  allele-
specific primers for C1388del (WT: 5′-AGG CTA CCA CAG
TGC CCC A-3′, LH: 5′-CAG GCT ACC ACA GTG CCC
A-3′) were amplified against an anchor primer (5′-CTC ACC
CAG GTG TGT GTT TG-3′), using 1.5 mM MgCl2, 0.4 µM
of each primer, 0.2 µM of each dNTP, and 0.875 U Taq
polymerase (Invitrogen, Carlsbad, CA) on 50 ng of genomic
TABLE 1. CONTINUED.
Evaluated cmr mutations
continued
Breed # mutation/disease
  Kuvasz 1  
  Lancashire heeler 1  
  Lapponian herder 54 cmr3
  Löwchen 1  
  Miniature schnauzer 2  
  Neapolitan mastiff 2  
  Newfoundland 3  
  Norfolk terrier 1  
  Norrbottenspetz 1  
  Norwegian elkhound 2  
  Parson russel terrier 5  
  Pyrenean mastiff 7  
  Rottweiler 1  
  Russian hound 1  
  Samoyed 4  
  Spanish mastiff 6  
  Swedish vallhund 2  
  Tibetan spaniel 2  
        A total of 179 individuals from 25 different breeds diagnosed with retinopathy, retinal degenerations, or unspecified retinal
        changes  were  sequenced  for  either the  complete  cBEST1      coding region  or  exon  10 only. In  addition  to  two mutations
        (P463FS, G489V) identified in cmr3 affected Lapponian herder, three novel polymorphisms (Table 2) and five heterozygote
        sequence   variations   were observed. Subsequently, all 614 dogs from 38 breeds enrolled in the study were evaluated for cmr1,
        cmr2, and cmr3 mutations.
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2794DNA in 35 cycles at 94 °C for 45 s, 69 °C for 30 s, and 72 °C
for 30 s, after an initial denaturation at 94 °C for 1 min and
followed by a final extension at 72 °C for 10 min. The 420-
bp PCR product was separated on 6% polyacrylamide gels and
scored based on the presence or absence of DNA product. The
G1466T test used the same anchor primer combined with
primers specific to the respective alleles (WT: 5′-CCT ACG
CAG AGT CTC AGG G-3′, LH: 5′-CCT ACG CAG AGT
CTC AGT G-3′). Amplification and genotyping of the 342-bp
PCR product was obtained and evaluated under the same
conditions as cmr3, substituting the annealing temperature for
68 °C (WT) and 67 °C (LH), respectively.
Restriction enzyme digest—Coding changes identified
in the BMD were screened in all individuals of the breed by
either direct sequencing, as described above (BEST1 sequence
comparison), or restriction enzyme tests. Thus, cBEST1 exon
10  was  amplified  and  subsequently  digested  at  37  °C
overnight with StuI, BstNI, and BbsI (New England Biolabs,
Ipswich,  MA)  to  assess  the  Lys438Arg,  Trp440Cys,  and
Val473Gly  substitutions,  respectively.  Resulting  DNA
patterns were evaluated on 1% agarose gels reflecting the a)
Lys438Arg WT allele (A) by 304- and 521-bp bands versus
the 825-bp mutant allele (G); b) Trp440Cys WT allele (G) by
36- and 185-bp bands compared to a 121-bp allele for the
mutant allele (T) in addition to 38-, 54-, 84-, 186-, and 242-
bp bands present with both genotypes; c) Val473Gly WT
allele (T) by 100- and 426-bp bands in contrast to a 526-bp
band indicating the mutant allele (G) next to 107- and 192-bp
products being present with both genotypes.
Intron  2  and  3  polymorphism  screening—Two
polymorphisms in introns 2 and 3 (Table 2, #2 and #3) were
assessed in LH by restriction enzyme digest. Single nucleotide
polymorphism (SNP) 57,507,851 (C/T) was located within a
346-bp PCR product (primers 5′-ACT TAT GAG GCC CAG
ACA  AGC-3′  and  5′-TGA  ATG  GCT  GGC  TAT  TTG
TTC-3′) obtained from 50 ng genomic DNA with 1.5 mM
MgCl2, 0.625 µM of each primer, 0.2 µM of each dNTP, and
0.875  U  Qiagen  Taq  polymerase  in  35  cycles  at  60  °C
annealing temperature. The PCR product was digested with
20 U of Eco01091 (New England Biolabs) at 37 °C for 1 h,
resulting in a diagnostic product of either 213 bp (C) or 259
bp (T) in size. Similarly, SNP 57,506,423 (C/T) was included
in a 561-bp PCR product (primers 5′-GTG TGC TCC CAG
TGT CTA CAT C-3′ and 5′-CAC GAC CAG AGT CAC GTA
GAA G-3′), using the same conditions as described above at
65 °C annealing temperature. Digestion was achieved with 20
U of AatII (New England Biolabs) at 37 °C for 2 h. The
presence of 237- and 314-bp bands distinguished the common
allele (C) from the minor allele (T) which had 259- and 302-
bp products.
RESULTS
Retinal phenotypes: Retinal fundus phenotypes observed in
LH and other dog breeds can be related to several different
recognized disease variations. The LH breed is known to
segregate autosomal recessive prcd and a non-prcd form of
generalized retinal degeneration. Several additional retinal
abnormalities also were observed, including acquired post-
inflammatory changes, and more commonly a spectrum of
fundus  changes  referred  to  as  multifocal  retinal  dysplasia
(MRD [30]). This latter phenotype is characterized generally
by retinal folds and small hyporeflective areas in one or both
eyes (Figure 1A,B) that are more frequent in younger animals
and become less prominent or disappear in older adults. A
subset of LH dogs examined presented with multiple elevated
subretinal  brown-gray  lesions  (Figure  1C,D)  similar  to
previously described cmr ( [24], Figure 1E). The particular
hallmarks of this fundus appearance were bilateral expression,
larger lesions as compared to MRD, and clear indication of
retinal elevation, often in combination with lighter areas of
fluid accumulation next to or around the darker center of the
lesions (Figure 1D). Pedigree analysis revealed autosomal
recessive inheritance for the cmr phenotype (Figure 2) but did
not definitively determine if MRD and cmr comprise the same
or independent genetic traits. To further evaluate the genetic
basis  for  these  phenotypes,  BEST1  was  considered  as  a
candidate gene for retinal disease in LH and isolated cases
from three additional breeds, Karelian beardog, Kuvasz, and
Swedish vallhund, diagnosed with MRD.
BEST1 mutations: A total of 614 animals from 38 individual
breeds (Table 1), including LH, were selected based on (a)
results  of  the  above  described  phenotype  evaluation  and
subsequent outcomes of presented screens (BMD); (b) known
involvement  with  cmr1  but  originating  from  European
populations not previously screened (Dogue de Bordeaux and
English mastiff); (c) known mastiff origin (e.g., Italian cane
corso  and  Neapolitan  mastiff);  (d)  control  breeds  (e.g.,
Norwegian elkhound and Samoyed).
Initially,  affected  animals  from  selected  breeds  with
typical cmr changes and three LH that were obligate cmr
carriers (Table 1) had the complete cBEST1 coding region and
corresponding  exon–intron  boundaries  sequenced.  Several
known  and  novel  (NCBI  ss250608388-ss250608389,
ss250608394-ss250608401) polymorphisms were identified
in these samples (Table 2). Of these, two coding changes that
differ  from  the  WT  cBEST1  sequence  were  found
homozygous in affected LH; a deletion at nucleotide position
1,388  of  the  open  reading  frame  (Figure  3A;  NCBI
ss250608397), and a substitution at nucleotide position 1,466
(Figure 3B; NCBI ss250608399). The C1388del results in a
frame shift (Pro463fs) introducing a new stop codon at amino
acid  490.  The  G1466T  substitution  by  itself  leads  to  a
conservative change in the amino acid sequence (Gly489Val),
which is predicted to change the protein function with only
marginal significance (SIFT p=0.05; Table 3). In combination
with the C1388del, however, the G1466T substitutions results
in an additional stop codon at amino acid position 489 within
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2795the shifted reading frame (Gly489X). Since the mutations
have only been found in complete linkage disequilibrium, we
conclude that the combination of changes results in the disease
we now refer to as cmr3. Notably, both positions appear highly
conserved  in  the  BEST1  gene  of  different  species  at  the
nucleotide (Figure 3C) and amino acid level (Figure 3D).
The three sequenced obligate LH carrier animals were
homozygous for the complete cBEST1 coding region, with the
exception  of  the  above-mentioned  mutations  and  two
polymorphisms in introns 2 and 3 (Table 2, #2 and #3; SNP
57,507,851  [BICF2P299043]  [27];  SNP  57,506,423  [24]).
Although both mutations in exon 10 were found to be linked
to  each  other  and  the  cmr  phenotype,  the  intronic
polymorphisms  were  dissociated  with  the  mutations  or
disease status (data not shown) and therefore cannot predict
disease status in the breed.
Focusing on cBEST1 exon 10, sequence of this exon was
obtained from samples of an additional 21 breeds reported to
segregate  retinopathies  and/or  unspecified  retinal  changes
(Table 1). None of the investigated animals carried the cmr3
mutation alleles, but five additional sequence alterations were
identified (Table 2 and Table 3).These were analyzed for their
potential deleterious effects using SIFT. Two conservative
changes in one individual each of the Norfolk terrier and
Jämthund  breeds  were  not  predicted  to  impact  protein
function  (p=0.67  and  0.75).  Similarly,  a  Lys438Arg
substitution identified in two heterozygous BMD does not
affect a critical position in the bestrophin protein (p=0.44)
even though this amino acid is highly conserved between
species  (Figure  3D).  The  remaining  two  mutations,
Trp440Cys  and  Val473Gly,  have  high  potential  to  alter
molecular properties (p=0.02 in each case). Both were found
in the heterozygous state in BMD at an allele frequency of less
than 1% (0.5 and 0.1%, respectively, based on 392 individual
dogs),  and  no  homozygous-affected  animal  has  been
identified thus far.
Subsequent  genotyping  of  the  cmr1,  cmr2,  and  cmr3
mutations confirmed segregation of cmr1 in three mastiff-
related breeds from Italian kennels: the Dogue de Bordeaux,
English mastiff, and Italian cane corso (Table 3).
Genotype–phenotype  correlation:  The  two  novel  cmr3
mutations found exclusively in the LH breed were in complete
linkage equilibrium and homozygous in all animals diagnosed
with the cmr phenotype (Table 4). Pedigree analysis further
supported  segregation  of  the  mutations  with  the  cmr
phenotype (Figure 2). None of the individuals with either post-
TABLE 2. OBSERVED GENOMIC VARIATION IN THE CBEST1 GENE.
Number CFA18 bp Gene
position
Variation Consequence Observed in Reference
1 57507965 Exon 2 G>A silent Karelian beardog (KBD) [24]
2 58507851 Intron 2 C>T non-coding Lapponian herder BICF2P2990432
3 57506423 Intron 3 C>T non-coding three or more breeds [24]
4 57506082 Exon 4 C>A silent three or more breeds [24]
5 57505871 Intron 4 G>A non-coding Swedish vallhund (SV) [24]
6 57505579 Intron 4 A>G non-coding Kuvasz [24]
7 57505571 Intron 4 A>G non-coding KBD, SV BICF2G6306892812
8 57505345 Intron 5 C>T non-coding Kuvasz [24]
9 57505321 Intron 5 T>C non-coding Kuvasz [24]
10 57505315 Intron 5 C>A non-coding Kuvasz [24]
11 57504881 Intron 5 C>G non-coding Swedish vallhund [24]
12 57504859 Intron 5 A>G non-coding KBD, SV NCBI ss250608388
13 57504620 Intron 6 G>A non-coding three or more breeds BICF2G6306892832
14 57504059 Intron 6 T>A non-coding Swedish vallhund BICF2G6306892862
15 57503846 Exon 7 G>A silent three or more breeds BICF2G6306892872
16 57503789 Intron 7 A>G non-coding three or more breeds BICF2G6306892882
17 57502488 Intron 7 A>G non-coding Swedish vallhund BICFPJ14562051
18 57502387 Exon 8 T>C silent Karelian beardog NCBI ss250608389
19 57502384 Exon 8 T>C silent KBD, SV BICFPJ14562061
20 57500034 Exon 10 A>G Lys438Arg Bernese mountain dog NCBI ss250608394
21 57500028 Exon 10 G>T Trp440Leu Norfolk terrier NCBI ss250608395
22 57500027 Exon 10 G>T Trp440Cys Bernese mountain dog NCBI ss250608396
23 57499959 Exon 10 C>del Pro463fs Lapponian herder NCBI ss250608397
24 57499929 Exon 10 T>G Val473Gly Bernese mountain dog NCBI ss250608398
25 57499881 Exon 10 G>T Gly489Val Lapponian herder NCBI ss250608399
26 57499834 Exon 10 A>T Thr505Ser Jämthund NCBI ss250608400
27 57449754 Exon 10 C>T silent three or more breeds NCBI ss250608401
28 57498425 3′UTR A>T non-coding Swedish vallhund [24]
          The majority of polymorphisms identified had previously been reported. Three new polymorphisms (row #12, 18, and 27),
          however, were observed in addition to seven coding changes in exon 10 (row #20–26); two of these segregate with retinal disease
          in the Lapponian herder breed (row #23 and 25, bold, cmr3). *CFA18=Canis familiaris chromosome 18. 1Based on CanFam1; Based
          on Can Fam2.
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2Figure 1. Multifocal retinal dysplasia and canine multifocal retinopathy (cmr) fundus phenotypes. Fundus appearance associated with
multifocal retinal dysplasia (MRD; A, B) compared to canine multifocal retinopathy 3 (cmr3; C, D), canine multifocal retinopathy 1 (cmr1;
E), and a normal reference fundus (F). A-B: MRD: retinal folds with hyporeflective areas. Smaller lesions (arrows) can appear similar to
cmr, particularly in dogs that have only one or few folds. C-D: cmr3: Multiple brown-gray oval lesions located subretinally (C, arrows) that
generally are of smaller diameter than the optic disc. Lesions are elevated and are surrounded by a “halo” of presumably clear subretinal fluid
(D, arrow). E. Lesions typical for cmr1 (arrows). F: Normal fundus appearance.
Molecular Vision 2010; 16:2791-2804 <http://www.molvis.org/molvis/v16/a299> © 2010 Molecular Vision
2797inflammatory  lesions  or  a  normal  fundus  were  affected.
However, a single animal initially diagnosed with MRD but
not cmr also carried the cmr3 alleles on both chromosomes
(Figure 2, gray arrow), as did another animal diagnosed with
generalized  retinal  degeneration  (PRA;  Figure  2,  black
arrow). Some animals affected with MRD (Figure 2, gray)
were heterozygous for the cmr3 mutations, but half of the
MRD-affected cases typed normal at the cmr3 loci (Table 4),
supporting a disparate genetic basis. It has to be pointed out
that  the  cmr3-affected  individual  diagnosed  with  PRA  is
related to non-prcd PRA-affected cases that do not carry the
cmr3 alleles homozygously. A common ancestor between
these animals (Figure 2, *) indicates that the observed retinal
degeneration could be a result of non-prcd PRA and mask
expression of typical cmr fundus changes based on the severe
alterations to the retina.
DISCUSSION
In the present study, a total of 614 dogs from 38 breeds were
examined for published cmr mutations (cmr1 and cmr2) and
then evaluated for the presence of previously unidentified
mutations  resulting  in  a  cmr-like  phenotype.  Our  results
(Table 1) confirm segregation of cmr1 in three mastiff-related
breeds from Italy: Dogue de Bordeaux, English mastiff, and
Italian cane corso (Table 1). The presence of the cmr1 allele
in the mastiff population is independent of their geographic
origin, which dates the original mutation event back to the
beginning of the development of this distinct cluster of dog
breeds [31]. The lack of the mutation in the Argentinean,
Neapolitan, Pyrenean, and Spanish mastiffs is likely due to
the small number of available samples examined rather than
the exclusion of the disease from these breeds. No additional
breeds were found to carry cmr1 alleles at this point, even
when screened animals exhibited a disease phenotype highly
compatible  with  the  disease.  We  therefore  conclude  that
cmr1 is generally present in mastiff-related breeds. On the
other hand, cmr2 is likely limited to the Coton de Tulear, a
breed originating in Madagascar under the strict control of the
royal  house  and  isolated  for  many  generations  before
distribution of a limited breeding stock around the world over
the past 35 years. Most notably we have identified a novel
cmr mutation, cmr3, which was observed selectively in LH.
Originally used as reindeer-herding dogs by the Sami people
of  Northern  Europe,  the  breed  is  thought  to  have  been
recreated after a population bottle neck during the Second
World War. Although breeding records indicate admixture
Figure  2.  Representative  Lapponian
herder  pedigree  analyzed  for  canine
multifocal  retinopathy  3  (cmr3)
mutations.  All  animals  clinically
affected  with  cmr3  (red)  are
homozygous  for  the  identified  cmr3
haplotype  (AA),  as  is  one  individual
presenting multifocal retinal dysplasia
(MRD; gray, arrow). Additionally, one
dog diagnosed with progressive retinal
atrophy (PRA) at 8 years of age (black,
arrow) shares the disease haplotype; at
the same time this animal is related to
non-progressive rod-cone degeneration
(prcd) PRA-affected dogs through one
of its ancestors (*; extended pedigree
not  shown).  Abbreviations:  AB
represents the heterozygote haplotype;
BB represents the wild-type haplotype,
N/A is not available.
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Figure 3. Mutations identified in LH affected with canine multifocal retinopathy 3 (cmr3). A C1388del/Pro463fs mutation (A, boxed) and
linked G1466T/Gly489Val nucleotide substitution (B, boxed) were identified in canine bestrophin 1 (cBEST1) exon 10 of cmr3-affected
Lapponian herder (LH). Wild-type sequence and resulting amino acids are identified on top (codons are separated by dotted lines), while the
mutations and resulting amino acid changes are noted on the bottom. Note that the Gly489Val substitution leads to a stop codon within the
Pro463fs altered reading frame. The carrier sequence in the middle is heterozygous for both changes. WT=wild type, C=carrier, A=cmr3
affected. C: Conservation of the nucleotide sequence between species. D: Comparison of partial bestrophin exon 10, amino acid 436 to 507
between different species demonstrates the conservation of identified variants. Positions 438, 440, 463, 473, 489, and 505 are highlighted in
red.  Dog=Canis  familiaris,  Cow=Bos  taurus,  Pig=Sus  scrofa,  Human=Homo  sapiens,  Chimp=Pan  troglodytes,  Macaca=Macaca
fascicularis. “.”=position identical to Dog.with other local breeds, including the Karelian beardog, the
mutation may either have occurred or been preserved only in
those lines leading to the modern dog breed now constituting
the LH.
Even though cmr and MRD are distinct and separable
retinal  disorders  in  dogs,  they  share  enough  clinical
similarities that could make specific diagnosis difficult. To
this end, individuals from four breeds (Table 1), diagnosed
with  either  MRD  (Karelian  beardog,  Kuvasz,  Swedish
vallhund)  or  cmr-compatible  fundus  changes  (LH),  were
screened for mutations in the cBEST1 coding region. Two
novel  sequence  alterations  (C1388del/Pro463fs,  G1466T/
Gly489Val) in exon 10 segregated only with the LH cmr3
(Figure 2). The C1388del microdeletion (Figure 3A) initiates
a Pro463fs frame shift that results in a stop codon at amino
acid 490. To date, the G1466T/Gly489Val substitution has not
been observed without the upstream C1388del microdeletion,
and the resulting inherent pathogenic effect has therefore not
yet  been  established.  Within  the  context  of  the  upstream
mutated reading frame, the G1466T mutation coded for an
additional Gly489X stop codon (Figure 3B). These findings
strongly indicate that the identified mutations shorten the 585-
amino acid bestrophin to a 488-amino acid protein with an
altered C-terminus.
The amino acid position and translational consequence of
the cmr3 mutations are distinctly different from the cmr1 stop
mutation  (no  protein)  and  the  cmr2  missense  mutation
(mislocalization; Guziewicz et al., submitted), all resulting in
highly similar phenotypes (Figure 1). The cmr3 mutations
likely will not affect bestrophin targeting to the basolateral
membrane  of  the  retinal  pigment  epithelium,  but  protein
function might be impacted by the loss of interaction between
the bestrophin C and N-terminus [32]. The bestrophin C-
terminus  has  also  been  implicated  in  the  activation  and
TABLE 3. DOG BREEDS ASSOCIATED WITH CBEST1 SEQUENCE VARIATIONS.
Breed CFA18 bp variant aa change disease Significance (p)
Bernese mountain dog 57500034 A1313G* Lys438Arg - 0.44
  57500027 G1320T* Trp440Cys - 0.02
  57499929 T1418G* Val473Gly - 0.02
Dogue de Bordeaux 57507861 C73T R25X cmr1 stop
English mastiff 57507861 C73T R25X cmr1 stop
Italian cane corso 57507861 C73T R25X cmr1 stop
Jämthund 57499834 A1513T* Thr505Ser - 0.75
Lapponian herder 57499959 C1388del Pro463fs cmr3 frame shift
  57499881 G1466T Gly489Val cmr3 0.05
Norfolk terrier 57500028 G1319T* Trp440Leu - 0.67
        New sequence alterations were identified in cBEST1 exon 10 in Bernese mountain dog, Jämthund, Lapponian herder, and
        Norfolk terrier breeds. Three dog breeds from Italian kennels (Dogue de Bordeaux, English mastiff, Italian cane corso) were
        found to carry the cmr1 allele [24] in concordance with their mastiff-related background, while the two mutations in the
        Lapponian herder segregate with an independent disease form, termed cmr3. Significance of probability for missense mutations
        to alter protein function was calculated using SIFT (column six; Significance [p]). *Changes were observed in heterozygote
        state only.
TABLE 4. LAPPONIAN HERDER PHENOTYPE-GENOTYPE ASSOCIATION.
    cmr3 genotype Age of diagnosis
Phenotype Total normal carrier affected average years
normal 31 18 13 0 3–12
MRD 8 4 3 1 2–11
PInf 3 2 1 0 3.0
cmr 8 0 0 8 1.8
PRA 4 1 2 1 7.25
Total 54 25 19 10  
Fundus exams of Lapponian herder (LH) identified multifocal retinal dystrophy (MRD), post-inflammatory lesions (PInf),
canine multifocal retinopathy (cmr), and generalized progressive retinal atrophy, not associated with prcd (PRA). Identified
cmr3 mutations segregate with cmr (shaded), with two exceptions in other phenotypes (details in text). Most notably, the average
age of onset for disease is less than 2 years of age, while PRA typically occurs at a later age. Most variation of disease onset
and expression occurs with MRD.
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2800regulation of the channel function [33,34], even though most
predicted  domains  are  located  upstream  of  the  cmr3
mutations.  Additionally,  participation  in  channel
multimerization  [35]  and  direct  involvement  of  the  C-
terminus in the activation or regulation by Ca2+ and other
physiologic  processes  has  been  proposed  [36].  However,
these  predictions  are  mainly  based  on  hypothesized
localization  of  phosphorylation  sites  or  binding  sites  for
kinases,  such  as  protein  kinase  A  or  extracellular  signal-
regulated  kinases  (Erk)  [37].  Since  few  human  BEST1
mutations are located within the C-terminal part of bestrophin
[7], the cmr3 model provides initial clinical evidence for a
functional  role  of  the  BEST1  C-terminus.  Thus,  the
identification of a third nonallelic form of cmr will further
contribute to the investigation of BEST1 disease mechanisms
relevant to canines and humans.
BEST1 exon 10 was sequenced in a larger number of
breeds  (Table  1)  and  presented  an  additional  five  new
sequence alterations (Table 3). Two of these, Thr505Ser and
Trp440Leu, were found in the heterozygous state in a single
Jämthund and Norfolk terrier, respectively. Clinical reports
for these animals did not indicate any retinal changes, and no
other  individuals  from  the  breeds  were  available  for
genotyping. More importantly, both sequence changes are
conservative and are not expected to impact protein function
[28,29]. Thus, they are not considered to be associated with
retinal disease and were not investigated further. Surprisingly,
three  independent  substitutions  were  present  in  the  BMD
breed. Two of these (Trp440Cys and Val473Gly) are likely
deleterious (Table 3) and located  in  a  region  that  is  con-
served  between species (Figure 3D), but  neither was found
homozygous in an animal with retinal disease. Because of the
low allele frequency (< 1%) of these two potential mutations,
it is likely that very few if any affected animals will occur in
the  breed.  Hence,  the  contribution  of  these  mutations  to
disease risk cannot be evaluated without further elucidating
the functional properties of the BEST1 C-terminus.
Pedigree analysis of cmr3 supports autosomal recessive
inheritance with the predominant clinical appearance similar
to cmr (Table 4, Figure 2). The partial overlap in phenotype
with  prcd  [22],  MRD,  and  non-prcd  PRA,  however,
complicates the characterization of the potential phenotypic
variation for each individual trait. Above all, some similarities
in the appearance of the fundus lesions in MRD and cmr
(Figure 1) and lack of a clear definition of the MRD phenotype
[30] can raise questions with cases that develop either atypical
or  only  few  lesions.  In  strict  contrast  to  MRD,  the  cmr
phenotype always presents bilaterally. Nevertheless, several
cmr3  heterozygote  animals  exhibit  a  bilateral  MRD
phenotype, as does one animals homozygous for the mutations
(Figure 2, gray arrow). The latter was diagnosed at 7 years of
age with minor changes in both eyes consistent with MRD.
Earlier exams list no retinal abnormalities at 1.5 years of age,
and multiple “rosettes” in the right eye at 5 years of age.
Another cmr3-affected animal (Figure 2, black arrow) was
diagnosed with generalized retinal degeneration during the
first available fundus exam at 8 years of age. Three additional
animals with non-prcd PRA shared common ancestry with
this individual; two of these were carriers and one was normal
for the cmr3 mutations. Thus, the observed phenotype could
be the consequence of non-prcd PRA segregating in the breed.
Without early clinical data, we cannot determine whether
cmr-related retinal changes were present at an earlier time
point.
Longitudinal studies of several cmr3-affected animals
suggest that fluctuations in the appearance and presence of
multifocal lesions can occur. This includes the age of onset
(between  9  months  and  2  years)  as  well  as  extent  and
progression of lesions; in fact some of the individual cmr
lesions  can  disappear  over  time.  The  age  of  onset  was
observed as early as 11 weeks for cmr1 [38,39] and 15 weeks
for cmr2 [40], with little or no progression of the lesions
beyond  1  year  of  age.  However,  diminished
electroretinograms suggest that Cotons affected with cmr2
develop retinal degeneration that can be more extensive than
the focal lesion [40]. This is caused by the resolution of the
detachment  resulting  in  hypertrophic-  and  hyperplastic-
pigmented retinal epithelium and focal outer retinal thinning.
In some older animals with extensive lesions, confluence of
these areas can lead to a generalized retinal degeneration. The
degenerative process occurs earlier in Great Pyrenees (cmr1)
and is more likely to result in focal rather than generalized
retinal  degeneration  [38,39].  Additionally,  the  lower  life
expectancy of this breed could prevent observing advanced
disease stages. However, at least one cmr1 case with resulting
generalized retinal degeneration has been observed clinically
and  confirmed  histopathologically  (Bruce  Grahn,  DVM,
Professor of Veterinary Ophthalmology and Associate Dean,
Western  College  of  Veterinary  Medicine,  University  of
Saskatchewan, Saskatoon, Canada). Association of BEST1
missense mutations with the human PRA equivalent Retinitis
Pigmentosa has recently been established [41]. Although there
is no current evidence that cmr causes PRA in the investigated
dog models, we suggest that generalized retinal degeneration
is a potential rare outcome of the disorder and can mimic a
PRA phenotype in older animals.
Based on our current findings, we propose the following
hypothetical working model for cmr3 genotype–phenotype
correlations (Figure 4): (a) the majority of cmr3 homozygous-
affected dogs have a typical cmr phenotype (Figure 1C,D); (b)
at the extremes, a very small number of animals can develop
a  more  subtle  phenotype  indistinguishable  from  MRD  or
generalized retinal degeneration phenotypically identical to
PRA; (c) carriers for cmr3 are asymptomatic, although a few
particularly  susceptible  individuals  can  develop  MRD,
possibly  using  a  similar  mechanistic  basis  as  autosomal
dominant  BEST1-related  human  disorders.  To  test  this
hypothesis we will need to characterize a larger portion of the
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Indeed, the establishment of an accurate classification system
will aid in the development of categorized information from
diagnoses of less defined retinal changes or MRD [30] and
would be further simplified by the identification of other loci
responsible for MRD or PRA. For this it seems critical to
clinically examine dogs at risk between 1 and 2 years of age
and  provide  yearly  follow-up  data  to  assess  phenotypic
variation. Along with the examination, we recommend that
photographic  documentation  be  performed  using  a
combination of wide-field and higher resolution images of
both eyes; the exact methods have previously been published
[42]. Detailed descriptions for canine retinal disorders would
enhance  our  ability  to  correctly  diagnose  inherited  and
acquired  diseases,  to  separate  multiple  genetic  traits  in
individual breeds, and ultimately to scrutinize cmr genotype–
phenotype associations.
In  summary,  the  currently  identified  mutations  in
cBEST1 indicate a significant contribution of these variations
to  retinal  disease  phenotypes,  comparable  to  the  human
ortholog. Continued efforts to follow and characterize cmr
mutations will certainly lay the foundation for understanding
phenotype variation and modification of bestrophinopathies
as well as promoting the development of new therapies.
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